Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

Diabetes Therapy

Volumn 9, Issue 1, 2018, Pages 49-66

  Grunberger, George ^a   Camp, Sarah ^b   Johnson, Jeremy ^b   Huyck, Susan ^b   Terra, Steven G ^c   Mancuso, James P ^c   Jiang, Zhi Wei ^d   Golm, Gregory ^b   Engel, Samuel S ^b   Lauring, Brett ^b  

^a Grunberger Diabetes Institute   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PFIZER INC   (United States)

^d MSD China ^*  (China)

Author keywords

Chronic kidney disease; Ertugliflozin; Glycemic control; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ERTUGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; PLACEBO; ROSIGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA;

ARTICLE; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CLINICAL EVALUATION; CLINICAL PRACTICE; COHORT ANALYSIS; CONSULTATION; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; EVALUATION AND FOLLOW UP; FEMALE; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HUMAN; HYPOGLYCEMIA; HYPOVOLEMIA; INCIDENCE; KIDNEY FUNCTION; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MAGNITUDE ESTIMATION METHOD; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MICROALBUMINURIA; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION;

EID: 85041497164     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-017-0337-5     Document Type: Article

References (28)

1. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215–25.
2. Dandona P, Chaudhuri A. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: an overview for the primary care physician. Int J Clin Pract. 2017;71:e12937.
3. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.
4. Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016;39(Suppl 2):S165–71.
5. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–71.
6. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369–84.
7. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–73.
8. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34.
9. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.
10. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–97.
11. Mascitti V, Maurer TS, Robinson RP, Bian J, Boustany-Kari CM, Brandt T, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011;54:2952–60.
12. AstraZeneca Pharmaceuticals. Summary of product characteristics—Forxiga, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002322/WC500136026.pdf. Accessed July 21, 2017.
13. ® (dapagliflozin) tablets, for oral use 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202293s009lbl.pdf. Accessed July 21, 2017.
14. ® (empagliflozin) tablets, for oral use, 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204629s000lbl.pdf. Accessed July 21, 2017.
15. Boehringer Ingelheim Pharmaceuticals I. Summary of product characteristics—Jardiance, 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002677/WC500168592.pdf. Accessed July 21, 2017.
16. Janssen Pharmaceuticals I. Highlights of prescribing information—INVOKANA (canagliflozin) tablets, for oral use, 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204042s015s019lbl.pdf. Accessed July 21, 2017.
17. Janssen-Cilag International N. Summary of product characteristics—Invokana 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002649/WC500156456.pdf. Accessed July 21, 2017.
18. American Diabetes Association. Executive summary: standards of medical care in diabetes—2012. Diabetes Care. 2012;35(Suppl 1):S4–10.
19. Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya Ser B. 2000;62:134–48.
20. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–26.
21. Gantz I, Sokolova L, Jain L, Iredale C, O’Neill E, Wei Z, et al. Use of prohibited medication, a potentially overlooked confounder in clinical trials: randomized omarigliptin (once-weekly DPP-4 inhibitor) monotherapy trial in 18–45 year-olds. Clin Ther. 2017;9:2024–37.
22. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function, 2017. https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed July 21, 2017.
23. Sahasrabudhe V, Terra S, Fountaine R, Hickman A, Saur D, Matschke K, et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2017;57:1432–43.
24. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–7.
25. Kadokura T, Zhang W, Krauwinkel W, Leeflang S, Keirns J, Taniuchi Y, et al. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. Clin Pharmacokinet. 2014;53:975–88.
26. Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16:215–22.
27. Terra SG, Focht K, Davies M, Frias J, Derosa G, Darekar A, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19:721–8.
28. Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014;40:64–74.